Fig. 3
From: SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas
SMARCB1 expression correlates with patient outcomes and EMT markers in chordomas. (A) Representative immunohistochemical staining of SMARCB1 in typical and chondroid chordomas, showing high and low expression patterns. Scale bars: 50 µm. (B) Kaplan–Meier survival curves stratified by SMARCB1 expression levels. Left: Progression-free survival (PFS). Right: Overall survival (OS). High SMARCB1 expression (red) is associated with significantly better outcomes compared to low SMARCB1 expression (blue). Dotted lines represent 95% confidence intervals. Median PFS: 120 months (high) vs. 52 months (low), P = 0.006. Median OS: 134 months (high) vs. 109 months (low), P = 0.017. n = 23 high expression and 19 low expression samples. (C) Representative immunohistochemical staining of EMT markers (E-cadherin, N-cadherin, cytokeratin, and vimentin) in chordoma samples with high and low SMARCB1 expression. Scale bars: 50 µm.
